CLAIMS

1. Use of a peptide in the manufacture of a medicament for modulating bile acid homeostasis in a subject, wherein the peptide has an amino acid sequence comprising SEQ ID NO:70 (M70), and wherein the subject has primary biliary cirrhosis (PBC), cholestasis, primary sclerosing cholangitis (PSC), bile acid diarrhea (BAD), pregnancy intrahepatic cholestasis (PIC), bile acid malabsorption, cirrhosis, fibrosis, non-alcoholic fatty liver disease (NAFLD), or nonalcoholic steatohepatitis (NASH).

2. The use of claim 1, wherein the peptide has an amino acid sequence consisting of SEQ ID NO:70.

3. Use of a peptide in the manufacture of a medicament for modulating bile acid homeostasis in a subject, wherein the peptide has an amino acid sequence comprising SEQ ID NO:69 (M69), and wherein the subject has PBC, cholestasis, PSC, BAD, PIC, bile acid malabsorption, cirrhosis, fibrosis, NAFLD, or NASH.

4. The use of claim 3, wherein the peptide has an amino acid sequence consisting of SEQ ID NO:69.

5. Use of a peptide in the manufacture of a medicament for modulating bile acid homeostasis in a subject, wherein the peptide has an amino acid sequence comprising SEQ ID NO:1 (M1), and wherein the subject has PBC, cholestasis, PSC, BAD, PIC, bile acid malabsorption, cirrhosis, fibrosis, NAFLD, or NASH.

6. The use of claim 5, wherein the peptide has an amino acid sequence consisting of SEQ ID NO:1.

7. Use of a peptide in the manufacture of a medicament for modulating bile acid homeostasis in a subject, wherein the peptide has an amino acid sequence comprising SEQ ID NO:2 (M2), and wherein the subject has PBC, cholestasis, PSC, BAD, PIC, bile acid malabsorption, cirrhosis, fibrosis, NAFLD, or NASH.

8. The use of claim 7, wherein the peptide has an amino acid sequence consisting of SEQ ID NO:2.

9. The use of any one of claims 1 to 8, wherein the peptide is fused with an immunoglobulin Fc region.

10. The use of any one of claims 1 to 9, wherein the peptide is formulated as a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

11. The use of any one of claims 1 to 10, wherein the medicament is prepared for administration to the subject in combination with a supplemental therapy.

12. The use of any one of claims 1 to 11, wherein the subject has PBC.

13. The use of any one of claims 1 to 11, wherein the subject has cholestasis.

14. The use of any one of claims 1 to 11, wherein the subject has PSC.

15. The use of any one of claims 1 to 11, wherein the subject has BAD.

16. The use of any one of claims 1 to 11, wherein the subject has PIC.

17. The use of any one of claims 1 to 11, wherein the subject has bile acid malabsorption.

18. The use of any one of claims 1 to 11, wherein the subject has NASH.

19. The use of any one of claims 1 to 11, wherein the subject has cirrhosis.

20. The use of any one of claims 1 to 11, wherein the subject has fibrosis.

21. The use of any one of claims 1 to 11, wherein the subject has NAFLD.

22. Use of a peptide in the manufacture of a medicament for reducing bile acid synthesis in a subject, wherein the peptide has an amino acid sequence comprising SEQ ID NO:70 (M70), and wherein the subject has PBC, cholestasis, PSC, BAD, PIC, bile acid malabsorption, cirrhosis, fibrosis, NAFLD, or NASH.

23. The use of claim 22, wherein the peptide has an amino acid sequence consisting of SEQ ID NO:70.

24. Use of a peptide in the manufacture of a medicament for reducing bile acid synthesis in a subject, wherein the peptide has an amino acid sequence comprising SEQ ID NO:69 (M69), and wherein the subject has PBC, cholestasis, PSC, BAD, PIC, bile acid malabsorption, cirrhosis, fibrosis, NAFLD, or NASH.

25. The use of claim 24, wherein the peptide has an amino acid sequence consisting of SEQ ID NO:69.

26. Use of a peptide in the manufacture of a medicament for reducing bile acid synthesis in a subject, wherein the peptide has an amino acid sequence comprising SEQ ID NO:1 (M1), and wherein the subject has PBC, cholestasis, PSC, BAD, PIC, bile acid malabsorption, cirrhosis, fibrosis, NAFLD, or NASH.

27. The use of claim 26, wherein the peptide has an amino acid sequence consisting of SEQ ID NO:1.

28. Use of a peptide in the manufacture of a medicament for reducing bile acid synthesis in a subject, wherein the peptide has an amino acid sequence comprising SEQ ID NO:2 (M2), and wherein the subject has PBC, cholestasis, PSC, BAD, PIC, bile acid malabsorption, cirrhosis, fibrosis, NAFLD, or NASH.

29. The use of claim 28, wherein the peptide has an amino acid sequence consisting of SEQ ID NO:2.

30. The use of any one of claims 22 to 29, wherein the peptide is fused with an immunoglobulin Fc region.

31. The use of any one of claims 22 to 30, wherein the peptide is formulated as a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

32. The use of any one of claims 22 to 31, wherein the medicament is prepared for administration to the subject in combination with a supplemental therapy.

33. The use of any one of claims 22 to 32, wherein the subject has PBC.

34. The use of any one of claims 22 to 32, wherein the subject has cholestasis.

35. The use of any one of claims 22 to 32, wherein the subject has PSC.

36. The use of any one of claims 22 to 32, wherein the subject has BAD.

37. The use of any one of claims 22 to 32, wherein the subject has PIC.

38. The use of any one of claims 22 to 32, wherein the subject has bile acid malabsorption.

39. The use of any one of claims 22 to 32, wherein the subject has NASH.

40. The use of any one of claims 22 to 32, wherein the subject has cirrhosis.

41. The use of any one of claims 22 to 32, wherein the subject has fibrosis.

42. The use of any one of claims 22 to 32, wherein the subject has NAFLD.

43. Use of a peptide in the manufacture of a medicament for reducing CYP7A1 levels in a subject, wherein the peptide has an amino acid sequence comprising SEQ ID NO:70 (M70), and wherein the subject has PBC, cholestasis, PSC, BAD, PIC, bile acid malabsorption, cirrhosis, fibrosis, NAFLD, or NASH.

44. The use of claim 43, wherein the peptide has an amino acid sequence consisting of SEQ ID NO:70.

45. Use of a peptide in the manufacture of a medicament for reducing CYP7A1 levels in a subject, wherein the peptide has an amino acid sequence comprising SEQ ID NO:69 (M69), and wherein the subject has PBC, cholestasis, PSC, BAD, PIC, bile acid malabsorption, cirrhosis, fibrosis, NAFLD, or NASH.

46. The use of claim 45, wherein the peptide has an amino acid sequence consisting of SEQ ID NO:69.

47. Use of a peptide in the manufacture of a medicament for reducing CYP7A1 levels in a subject, wherein the peptide has an amino acid sequence comprising SEQ ID NO:1 (M1),

and wherein the subject has PBC, cholestasis, PSC, BAD, PIC, bile acid malabsorption, cirrhosis, fibrosis, NAFLD, or NASH.

48. The use of claim 47, wherein the peptide has an amino acid sequence consisting of SEQ ID NO:1.

49. Use of a peptide in the manufacture of a medicament for reducing CYP7A1 levels in a subject, wherein the peptide has an amino acid sequence comprising SEQ ID NO:2 (M2), and wherein the subject has PBC, cholestasis, PSC, BAD, PIC, bile acid malabsorption, cirrhosis, fibrosis, NAFLD, or NASH.

50. The use of claim 49, wherein the peptide has an amino acid sequence consisting of SEQ ID NO:2.

51. The use of any one of claims 43 to 50, wherein the peptide is fused with an immunoglobulin Fc region.

52. The use of any one of claims 43 to 51, wherein the peptide is formulated as a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

53. The use of any one of claims 43 to 51, wherein the medicament is prepared for administration to the subject in combination with a supplemental therapy.

54. The use of any one of claims 43 to 51, wherein the subject has PBC.

55. The use of any one of claims 43 to 51, wherein the subject has cholestasis.

56. The use of any one of claims 43 to 51, wherein the subject has PSC.

57. The use of any one of claims 43 to 51, wherein the subject has BAD.

58. The use of any one of claims 43 to 51, wherein the subject has PIC.

59. The use of any one of claims 43 to 51, wherein the subject has bile acid malabsorption.

60. The use of any one of claims 43 to 51, wherein the subject has NASH.

61. The use of any one of claims 43 to 51, wherein the subject has cirrhosis.

62. The use of any one of claims 43 to 51, wherein the subject has fibrosis.

63. The use of any one of claims 43 to 51, wherein the subject has NAFLD.